Alopecia, Hair Diseases, Hair Loss
Conditions
Brief summary
The primary objective of the study was to assess the efficacy of DA-OTC-002 as a topical cosmetic hair treatment. The investigators conducted a prospective, institution-level, interventional, single-blinded, placebo-controlled investigation to assess the efficacy of a combination an alpha-1 agonist and a TAAR receptor agonist (DA-OTC-002) as a topical cosmetic hair treatment.
Detailed description
76 female subjects were included in the study. Subjects were otherwise healthy females, aged 18 years are older, and had ample hair on the scalp to allow application of test article. Subjects with an interfering dermatologic disease or procedure, who were pregnant, lactating, or planning to become pregnant during the study, had experienced a clinically important medical event within 90 days of the visit, who were actively treated for hypertension, or had known allergies to any excipient in DA-OTC-002 were excluded from the study. This study was conducted in compliance with Good Clinical Practice, including the archival of essential documents. All subjects gave informed consent during the study enrollment.
Interventions
COMBINATION_PRODUCTDA-OTC-002
The topical formula of DA-OTC-002 was formed from 2 molecules: an alpha 1 agonist (synephrine) and a TAAR receptor agonist A 1mL topical application of DA-OTC-002 was applied to a 10cm x 10xm target area of the right side of the scalp of each subject
Sponsors
Applied Biology, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Females Age 18 or older * Willing and able to apply the treatment as directed, comply with study * Subject has ample hair on the scalp to allow application of test article * Otherwise healthy. * Able to give informed consent
Exclusion criteria
* A medical history that may interfere with study objectives. * Subjects with any dermatologic disease in the treatment area. * Women who are pregnant, lactating, or planning to become pregnant during the study period. * Subjects who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc). * Subjects who are actively treated for hypertension. * Subjects who have known allergies to any excipient in DA-OTC-002 * Subjects who are currently participating in another clinical study or have completed another clinical study with an investigational drug or device in the treatment area within 30 days prior to study treatment initiation. * Subjects who have used any topical prescription medications in the treatment area within 30 days prior to study treatment initiation. * Subjects who have had a dermatological procedure such as surgery in the treatment area within 30 days prior to study treatment initiation. * Subject is unable to provide consent or make the allotted clinical visits.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reduction in Hair Shedding Assessed by Target Area Hair Count Shedding | 30 minutes | The average reduction in target area hair count after application of DA-OTC-002 |
Countries
Brazil
Outcome results
None listed